TeVido BioDevices Receives National Institutes of Health Phase I SBIR Grant

The award furthers research on 3D bioprinting of nipple areola complex for reconstruction in breast cancer survivors.

TeVido BioDevices, an early stage 3D bioprinting company creating natural human grafts for reconstructive procedures announced today that they have been awarded a Small Business Innovation Research (SBIR) Grant from the National Cancer Institute of the National Institutes of Health (NIH). The Phase I SBIR grant will be used to fund further pre-clinical development of the company’s novel solutions to address the challenges that post-mastectomy patients face during breast reconstruction.

Press Release